Hourly refreshSun, Oct 25, 2026

Press Release Database

Recent press releases, indexed by topic.
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
Results
Showing all · English · 37,755 itemsDownloadExcelTXT
SaaS · Healthcare

Filling a Surgeon's Surgical Calendar: Patient Flow Content Strategy Explained

MedFire Media outlines a done-for-you, multi-platform content strategy helping board-certified plastic surgeons build sustained visibility and convert more inquiries into booked consultations and surgical procedures. -- MedFire Media provides a fully managed, multi-platform content strategy built for board-certified plastic surgeons who are generating plastic surgery patient inquiries but struggling to turn them into

Oct 25 · 11:40MarketersMEDIA
Media · Marketing & advertising

High Traffic, Low Bookings: Plastic Surgery Lead Response Study Cited

MedFire Media highlights research on lead response timing, showing how delayed replies can cost plastic surgery practices consultation bookings, and outlines practical follow-up steps alongside its content marketing system. -- MedFire Media is drawing attention to a research finding on lead response timing and its bearing on plastic surgery practices that generate website inquiries but fail to convert enough of them

Oct 25 · 11:39MarketersMEDIA
In the wire

AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations

AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations

Oct 25 · 11:27GlobeNewswire
AI

Vokolla lets developers prepare a launch press release without leaving Claude, Cursor or Gemini

Vokolla's press release agent now connects to AI assistants and coding tools such as Claude, Cursor and Gemini, so developers can draft and check a launch announcement where they build

Oct 25 · 11:18PR Now
AI

Automating SEO and Link Building for AI Agents with Rapid Indexer's New MCP Server1

New York City, USA, Oct. 25, 2026 -- Agents running in Grok Bot, Muse, Dots and other MCP-ready apps can now send new pages and backlinks to Googlebot, check whether they're indexed and report back, all inside the same conversation.

Oct 25 · 11:06GlobeNewswire
In the wire

Unfair Links Launches a Link Building Service for Local Backlinks and Google Business Profile Matched Links

New York City, USA, Oct. 25, 2026 -- Founded by Rollo Unden and Oliver Fish, Unfair Links builds local backlinks matched to a business's Google Business Profile, country and language, and is now taking sign-ups for its beta waitlist.

Oct 25 · 11:02GlobeNewswire
In the wire

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median...

Oct 25 · 11:01PR Newswire
AI · Cybersecurity

Beyond GRC: DigitalXForce Pioneers AI-Powered Risk Operations with Global X-ROC™ Rollout

Enterprise TRiSCM™ innovator advances Continuous Control Assurance, cyber risk quantification and real-time Risk Operations across global enterprises, transforming traditional GRC into proactive Digital Trust DALLAS, Oct. 25, 2026 -- DigitalXForce, the AI-native Enterprise...

Oct 25 · 11:00PR Newswire
Biotech & pharma

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Media Release

Oct 25 · 11:00GlobeNewswire
Healthcare · Biotech & pharma

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma

Oct 25 · 11:00GlobeNewswire
In the wire

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population Side effects were mostly mild and manageable, and all 18 patients proceeded to surgery Netherlands Cancer Institute investigators are now enroll

Oct 25 · 11:00Business Wire